CoChat

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Open access
Hennrich, Ute, Kopka, Klaus · 2019 · Pharmaceuticals

The DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index; 6 of the 44 sources its claims cite were checked for support.

Abstract

As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.

Overview

CoChat Summary

## TL;DR

Lutathera® ([177Lu]Lu-DOTA-TATE) is presented as the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy (PRRT) for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors. The paper summarizes its mechanism, indication, dosing, manufacturing, and the clinical trial results that supported approval.

## Key findings

  • Lutathera® was approved by the EMA in 2017 and the FDA in 2018; the paper also notes Canadian approval in 2019.
  • Its active ingredient is [177Lu]Lu-DOTA-TATE, which combines lutetium-177 with the somatostatin analogue DOTA-TATE to target SSTR-expressing tumor cells and cause DNA single- and double-strand breaks.
  • The recommended treatment schedule is four infusions of 7.4 GBq every 8 weeks; intervals may be extended to 16 weeks if dose-modifying toxicity occurs.
  • In the NETTER-1 phase III trial (229 patients), progression-free survival favored [177Lu]Lu-DOTA-TATE plus octreotide LAR over high-dose octreotide LAR: 65% vs 11% of patients were progression-free at 20 months (p < 0.0001), median PFS was not reached vs 8.5 months, and objective response rate was 18% vs 3% (p < 0.001).

## Methods

  • Narrative review/overview of Lutathera® covering chemical properties, clinical indication, application, pharmacology/pharmacokinetics, manufacturing, and regulatory status.
  • Draws on published clinical studies and product monographs, including the Erasmus phase I/II study (1,214 patients) and the NETTER-1 phase III trial (229 patients).
  • Summarizes reported trial endpoints and pharmacokinetic/dosimetry data from the cited studies rather than presenting new original analyses.

## Limitations

  • The paper does not report any new original experimental or clinical data; it synthesizes prior literature and regulatory documents.
  • The text makes evident that some sections are only brief summaries and refer readers to product monographs or cited studies for details; this limits methodological depth and reproducibility of the review’s own synthesis.
  • Not stated in the paper.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ph12030114

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Structure of [177Lu]Lu-DOTA-TATE (Lutathera®). Simplified writing of complexation [18].
Figure 1 Structure of [177Lu]Lu-DOTA-TATE (Lutathera®). Simplified writing of complexation [18].CC BY · PubMed Central
Figure 2 Simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE.
Figure 2 Simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE.CC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 0 Not valid · 33 Not checked · 1 Own results and interpretations

12 more claims

Create a free account to see all 39 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Citations

Cites

Show all 24 references

Research works printed but not linked: 3

  1. Erion, 1999, High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model [abstract], J. Nucl. Med., 40, 223
  2. Nagy, 2004, Radionuclide Therapy, Handbook of Nuclear Chemistry, Volume 4, 315
  3. Rolleman, 1996, Inhibition of Renal Uptake of Indium-111-DTPAOctreotide, J. Nucl. Med., 37, 1388

Cited by

Items 301–400 of 426

Metadata

Authors
Hennrich, U., & Kopka, K.
Affiliations
German Cancer Research Center (DE)
Corresponding author
Hennrich, Ute
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2019-07-29
Volume
12
Issue
3
Pages
114
ISSN
1424-8247 (ISSN-L)
OpenAlex
W2965362447
Cited by
440
References
26
Citations by year
2026: 58 · 2025: 87 · 2024: 88 · 2023: 61 · 2022: 58 · 2021: 46 · 2020: 38 · 2019: 3
FWCI
5.29
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
177Lu-DOTATATE, lutetium-177, peptide receptor radionuclide therapy, somatostatin receptors, DOTATATE, gastroenteropancreatic neuroendocrine tumors, radiopharmaceuticals, targeted radionuclide therapy, DNA double-strand breaks, cancer cell death

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.